UNIVERSITY OF LEICESTER Patent applications |
Patent application number | Title | Published |
20150290263 | THERAPEUTIC BACTERIOPHAGES - The present invention relates to a panel of bacteriophage, wherein the panel comprise any one or more bacteriophage selected from the group consisting of:— NCTC 12081404, NCTC 12081405, NCTC 12081406, NCTC 12081407, NCTC 12081408, NCTC 12081409 and NCTC 12081410. The invention also relates to the use of such panels for treating | 10-15-2015 |
20150239985 | Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation - In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier. | 08-27-2015 |
20150092921 | METHODS AND APPARATUS FOR X-RAY DIFFRACTION - Methods and apparatus are provided for performing back-reflection energy-dispersive X-ray diffraction (XRD). This exhibits extremely low sensitivity to the morphology of the sample under investigation. As a consequence of this insensitivity, unprepared samples can be analysed using this method. For example, in a geological context, whole rock samples become amenable to analysis. A composite diffraction spectrum can be produced using information from different recorded spectra in different energy sub-ranges. The composite spectrum excludes fluorescence signals that would otherwise obscure the diffraction signals. | 04-02-2015 |
20150067897 | GENETICALLY MODIFIED NON-HUMAN MAMMALS AND CELLS - Genetically modified mammals are described which lack the mannan binding lectin associated serine protease MASP-2, together with methods and constructs for their production. Such mammals are useful as models for disorders of the complement system, and in the identification of treatments for such disorders. Also described are mammals which lack the associated protein MAp19; such mammals may also lack MASP-2. | 03-05-2015 |
20150064176 | METHODS FOR TREATING CONDITIONS ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION - In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier. | 03-05-2015 |
20140364507 | Methods for Identifying Inhibitors of Mannan-binding Lectin-associated Serine Protease (MASP) Proteins and Uses Thereof - This disclosure is directed to methods and compositions to inhibit MASP protein activity using small molecule inhibitors. In one aspect, the disclosure is directed to methods for identifying inhibitors of MASP protein activity, including methods of screening capable of inhibiting MASP protein activity. | 12-11-2014 |
20140221868 | APPARATUS AND METHODS FOR ASSESSING THE EFFECT OF LIGHT ON A SUBJECT'S PERCEPTION OF TINNITUS - A method of assessing the effect of viewing varying colours of light on a subject's perception of tinnitus, comprising the steps of: presenting a display in at least part of the subject's field of view; illuminating the display with coloured light in the visible spectrum using one or more variable sources; varying measurable values of the coloured light illuminating the display; and recording the measurable values of the coloured light illuminating the display at which the subject indicates a change in their perception of tinnitus. Also provided are methods of determining which tristimulus values of light can be used to alleviate a subject's perception of tinnitus, methods of producing data sets of measurable values of coloured light, use of coloured light, articles formulated to modify illumination of at least part of the visual field of a subject, a method of alleviating a subject's perception of tinnitus and use of apparatus for assessing the effect of viewing varying colours of light on a subject's perception of tinnitus. | 08-07-2014 |
20140205598 | Methods for Treating Disseminated Intravascular Coagulation by Inhibiting MASP-2 Dependent Complement Activation - In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. In one embodiment, the invention provides methods of treating a subject suffering from a complement mediated coagulation disorder, such as disseminated intravascular coagulation. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier. | 07-24-2014 |
20140056873 | Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation - In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier. | 02-27-2014 |
20140043460 | OPTICAL ARRANGEMENT - The present disclosure relates to an improved optical arrangement for an optical imaging system or the like, comprising: an optical device; a digital micromirror device having a plurality of individually addressable micromirrors; a convex mirror; and a concave mirror concentric to the convex mirror. The convex mirror and the concave mirror define an optical triplet which is located in an optical path with the digital micromirror device and the optical device. The concave mirror comprises two concave mirror sections, one or both concave mirror sections being moveable relative to the convex mirror so as to control an image mapping between the digital micromirror device and the optical device. | 02-13-2014 |
20130273053 | Compositions and Methods of Inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria - In one aspect, the invention provides methods and compositions for inhibiting MASP-3-dependent complement activation in a subject suffering from paroxysmal nocturnal hemoglobinuria by administering to the subject a composition comprising an amount of a MASP-3 inhibitory agent in an amount effective to inhibit MASP-3-dependent complement activation. In another aspect, the invention provides methods and compositions for increasing the survival of red blood cells in a subject suffering from paroxysmal nocturnal hemoglobinuria by administering to the subject a composition comprising an amount of at least one of a MASP-1 inhibitory agent and/or a MASP-3 inhibitory agent effective to increase the survival of red blood cells. In some embodiments, the subject is administered a MASP-2 inhibitory agent and a MASP-1 inhibitory agent, a MASP-2 inhibitory agent and a MASP-3 inhibitory agent administered, a MASP-3 inhibitory agent and a MASP-1 inhibitory agent, or a MASP-1 inhibitory agent, a MASP-2 inhibitory agent and a MASP-3 inhibitory agent. | 10-17-2013 |
20130103630 | FUZZY INFERENCE METHODS, AND APPARATUSES, SYSTEMS AND APPARATUS USING SUCH INFERENCE APPARATUS - A health monitoring system for complex networked apparatus includes a number of neuro-fuzzy inference apparatuses feeding inference results into a data fusion hierarchy. At each level in the hierarchy, fuzzy inference is applied to generate a desired output signal by processing selected input signals in accordance with a knowledge base defining fuzzy membership functions and fuzzy inference rules defined in advance. The knowledge base includes alternative definitions of membership functions and/or inference rules. The apparatus selects which definition to use according to environmental or other conditions, and predetermined selection criteria. | 04-25-2013 |
20130095094 | ASSAY - The invention provides assays and apparatuses for assessing the ability of certain orally-ingestible samples, such as saliva or foodstuffs to cause inflammation, and thus the health risk such samples can cause upon ingestion by a subject. The invention also provides an assay to monitor an individual's diet with regards to inflammation risk. The invention also extends to methods of preventing inflammatory diseases. | 04-18-2013 |
20130080376 | FUZZY INFERENCE APPARATUS AND METHODS, SYSTEMS AND APPARATUSES USING SUCH INFERENCE APPARATUS - A health monitoring system for complex networked apparatus includes a number of neuro-fuzzy inference apparatuses feeding inference results into a data fusion hierarchy. At each level in the hierarchy, fuzzy inference is applied to generate a desired output signal by processing selected input signals in accordance with a knowledge base defining fuzzy membership functions and fuzzy inference rules defined in advance. The knowledge base includes alternative definitions of membership functions and/or inference rules. The apparatus selects which definition to use according to environmental or other conditions, and predetermined selection criteria. | 03-28-2013 |
20120258095 | Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation - In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier. | 10-11-2012 |
20120130017 | PROCESS AND NEW COMPOUNDS - There is provided a novel process for preparing polyamides (in particular cyclic and hairpin polyamides) comprising the step of coupling an amine with a Boc-protected amino acid monomer in the presence of diphosgene and/or triphosgene. Such a process may be performed on a solid or solution phase. | 05-24-2012 |
20110091450 | METHODS FOR TREATING DISSEMINATED INTRAVASCULAR COAGULATION BY INHIBITING MASP-2 DEPENDENT COMPLEMENT ACTIVATION - In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. In one embodiment, the invention provides methods of treating a subject suffering from a complement mediated coagulation disorder, such as disseminated intravascular coagulation. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier. | 04-21-2011 |
20100184126 | SAMPLING DEVICE - A portable sampling device ( | 07-22-2010 |
20100144544 | FLUORESCENCE LABELLING - Fluorescence Labelling This invention generally relates to techniques for fluorescence labelling, and to methods, apparatus and computer program code for processing fluorescence signal data. A method of determining respective first and second degree-of-labelling signals for different respective first and second fluorophores associated with a common entity, the method comprising: determining a first fluorescence signal from said first and second fluorophores under first conditions; determining a second fluorescence signal from said first and second fluorophores under second conditions different to said first conditions; and determining said first and second degree-of-labelling signals for said first and second fluorophores from said first and second fluorescence signals; and wherein said determining of said first and second degree-of-labelling signals is responsive to at least one coupling value (c | 06-10-2010 |
20100099132 | BACTERIAL GROWTH INDUCER - The present invention relates to methods of preparing bacterial growth inducers, and in particular to novel bacterial growth inducers/resuscitators prepared by such methods. The invention extends to various applications of such growth inducers, for example in clinical and environmental diagnostics, in reviving not immediately culturable (NIC) bacteria, and in the analyses of microbial populations in blood, food and soil samples. | 04-22-2010 |
20100075969 | Angiogenesis - The invention provides medicaments comprising an agent, which selectively modulates β2-adrenergic receptor conformation, or receptor activity, or activation thereof. The medicaments may be used for treating diseases that are characterised by disorganized and/or abnormal vasculature, such as cancer and metastatic disease. The medicaments may also be used for promoting organized/normal branched vasculature. | 03-25-2010 |
20100032568 | DETECTION OF THE ENERGY OF PHOTONS FROM BIOLOGICAL ASSAYS - A cryogenic detector is used for detection in a biological assay. | 02-11-2010 |
20090325867 | RECEPTOR-SPECIFIC TUMOUR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGAND (TRAIL) VARIANTS - The invention relates to a tumour necrosis factor- (TNF-) related apoptosis-inducing ligand (TRAIL) which is capable of selectively signalling through death receptor 4 (DR4), comprising Y at position 189. Preferably the TRAIL further comprises 19 IL and/or 199V; preferably also 201R, 213W and 215D, and/or preferably further comprises 193S. The invention also relates to uses of such TRAIL mutants which are capable of selectively signalling through DR4 in the treatment of cancer, and in the manufacture of medicaments for use in treatment of cancer. Preferably the cancer is chronic lymphocytic leukaemia, mantle cell lymphoma or non-Hodgkin's lymphoma. The invention also relates to kits comprising same. | 12-31-2009 |
20090205058 | GENETICALLY MODIFIED NON-HUMAN MAMMALS AND CELLS - Genetically modified mammals are described which lack the mannan binding lectin associated serine protease MASP-2, together with methods and constructs for their production. Such mammals are useful as models for disorders of the complement system, and in the identification of treatments for such disorders. Also described are mammals which lack the associated protein MAp19; such mammals may also lack MASP-2. | 08-13-2009 |
20090194426 | EUTECTIC MIXTURES BASED UPON MULTIVALENT METAL IONS - There is provided a mixture having a freezing point of up to 50° C., formed by reaction between: (A) one molar equivalent of a salt of formula I (M | 08-06-2009 |